Isotretinoin Psychiatric Disorder Warning Strengthened
This article was originally published in The Pink Sheet Daily
Executive Summary
Revised labeling for isotretinoin (Roche's Accutane and generics) suggests prescribers ask patients about psychiatric disorders prior to treatment initiation and continue that discourse throughout treatment
You may also be interested in...
Health Canada Advisory Panel Recommends Increased Accutane Physician Education
Committee unanimously rejects patient registry system that would be similar to U.S. iPLEDGE risk management program.
Health Canada Advisory Panel Recommends Increased Accutane Physician Education
Committee unanimously rejects patient registry system that would be similar to U.S. iPLEDGE risk management program.
FDA Approves "Unprecedented" Risk Management Program For Accutane
Wholesalers, pharmacists, prescribers and patients will have added responsibility under the iPLEDGE program.